ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

<h4>Background</h4>Previous studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC). However, the evolution of the genomic landscap...

Full description

Bibliographic Details
Main Authors: Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS Genetics
Online Access:https://doi.org/10.1371/journal.pgen.1010563

Internet

https://doi.org/10.1371/journal.pgen.1010563

Similar Items